Apremilast

(Otezla)

Apremilast

Drug updated on 11/13/2023

Dosage FormTablet (oral; 10 mg, 20 mg, 30 mg)
Drug ClassPhosphodiesterase 4 (PDE4) inhibitors
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of adult patients with active psoriatic arthritis.
  • For the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
  • For the treatment of adult patients with oral ulcers associated with Behçet’s disease.

Product Monograph / Prescribing Information

Document TitleYearSource
Otezla (apremilast) Prescribing Information.2021Amgen Inc., Thousand Oaks, CA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Apremilast in palmoplantar psoriasis and palmoplantar pustulosis: a systematic review and meta-analysis.2023Dermatology and Therapy
Time to relapse after discontinuing systemic treatment for psoriasis: a systematic review.2022American Journal of Clinical Dermatology
Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year. 2022Journal of Dermatological Treatment
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. 2022Cochrane Database of Systematic Reviews
Biologics and small molecule inhibitors for treating hidradenitis suppurativa: a systematic review and meta-analysis.2022Biomedicines
Apremilast in psoriasis patients with serious comorbidities: a case series and systematic review of literature.2022Dermatology Practical & Conceptual
Combination therapy with apremilast and biologics for psoriasis: a systematic review.2022American Journal of Clinical Dermatology
Systematic review of newer agents for the management of alopecia areata in adults: Janus kinase inhibitors, biologics and phosphodiesterase-4 inhibitors.2022Journal of the European Academy of Dermatology & Venereology
Efficacy and safety of apremilast monotherapy in moderate-to-severe plaque psoriasis: A systematic review and meta-analysis.2022Dermatologic Therapy
Assessment report: Otezla. 2020EMA
Therapeutic options for patients with rare rheumatic diseases: a systematic review and meta-analysis.2020Orphanet Journal of Rare Diseases
Comparability of European League Against Rheumatology-recommended pharmacological treatments of oral ulcers associated with Behçet’s disease: a systematic literature review of randomized controlled trials.2020Open Access Rheumatology: Research and Reviews
Biologics and small molecules in patients with scalp psoriasis: a systematic review.2020Journal of Dermatological Treatment
Comparative efficacy and safety of targeted DMARDs for active psoriatic arthritis during induction therapy: a systematic review and network meta-analysis.2019Seminars in Arthritis and Rheumatism
Time until onset of action when treating psoriatic arthritis: meta-analysis and novel approach of generating confidence intervals.2019Rheumatology International
Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response.2019Journal of the European Academy of Dermatology and Venereology
Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis.2018Future Medicine
Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis.2018Journal of the American Academy of Dermatology
The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis.2018Journal of Dermatological Treatment
Biologicals and small molecules in psoriasis: a systematic review of economic evaluations.2018PLoS One
Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.2018Rheumatology International

Clinical Practice Guidelines